The supplemental New Drug Application (sNDA) for the 0.1mg strength was granted Priority Review by the Food and Drug Administration (FDA). The new 0.1mg strength auto-injector has a shorter needle ...

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...

Anaphylaxis is a serious, potentially life-threatening allergic reaction that can affect several organ systems in the body and may threaten breathing and blood circulation. The most common causes of ...

The US Food and Drug Administration (FDA) has approved the first nalmefene hydrochloride auto-injector (Zurnai; Purdue Pharma LP) for the treatment of known or suspected opioid overdose in people aged ...

Lindsay Green learned that her 2-year-old son, Everett, had a peanut allergy when he was around 10 months old, leading her to learn more about how to protect her baby. Now, she has taken this concern ...

Please provide your email address to receive an email when new articles are posted on . The epinephrine auto-injector AUVI-Q, used for the emergency treatment of anaphylaxis, will be available ...

WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug ...